Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial

Vilazodone is a selective serotonin reuptake inhibitor and 5-HT(1A) partial agonist approved for major depressive disorder (MDD) treatment in adults. This was a 10-week, multicenter, double-blind, placebo-controlled and active-controlled, fixed-dose trial (NCT01473381). Adult patients with MDD (Diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathews, Maju, Gommoll, Carl, Chen, Dalei, Nunez, Rene, Khan, Arif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314105/
https://www.ncbi.nlm.nih.gov/pubmed/25500685
http://dx.doi.org/10.1097/YIC.0000000000000057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314105/
https://www.ncbi.nlm.nih.gov/pubmed/25500685
http://dx.doi.org/10.1097/YIC.0000000000000057

Ejemplares similares